New Disease Compounds Research Library Launched by the Medical Research Council

The Medical Research Council (MRC) has teamed up with six pharmaceutical companies to create a disease compounds library for academic researchers around the world. The library is the latest product of the MRC’s Industry Asset Sharing Initiative, which comprises of 47 deprioritised compounds contributed by AstraZeneca, GlaxoSmithKline, Janssen, Pfizer, Takeda and UCB. Both pre-clinical and

Continue Reading

Pfizer Publish New Analysis Showing Long Term Therapy Slowed Progression of Rare Neurodegenerative Disease

Pfizer Inc. announced the recent publication of a post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid polyneuropathy (TTR-FAP). The analysis, which included patients with the Val30Met mutation treated over varying periods of up to 5 and a half years, showed that treatment with VYNDAQEL initiated during the

Continue Reading